PDCD1 and neoplasm: Alongside this approach, a new therapy targeting the immune system has been developed in recent years: these drugs are monoclonal antibodies that inhibit the programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) immune check-point, preventing the inhibition of the tumor cell-killing function of T-lymphocytes7.